Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew G Rees

Showing results (61-70 of 72) with videos related to

Pageof 8
Sort By:
Nature Genetics|June 2, 2025
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavageZheqi Li, Guillermo Peluffo, Laura E Stevens, et al.
Cancer Discovery|September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted CancersBrian Belmontes, Katherine K Slemmons, Chun Su, et al.
Nature Cancer|July 3, 2020
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profilingSteven M Corsello, Rohith T Nagari, Ryan D Spangler, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature Communications|June 5, 2019
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaPratiti Bandopadhayay, Federica Piccioni, Ryan O'Rourke, et al.
Nature|May 6, 2026
Expanding the human proteome with microproteins and peptideinsEric W Deutsch, Leron W Kok, Jonathan M Mudge, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 8

Showing results (61-70 of 72) with videos related to

Sort By:
Pageof 8
Nature Genetics|June 2, 2025
KDM4C inhibition blocks tumor growth in basal breast cancer by promoting cathepsin L-mediated histone H3 cleavageZheqi Li, Guillermo Peluffo, Laura E Stevens, et al.
Cancer Discovery|September 16, 2024
AMG 193, a Clinical Stage MTA-Cooperative PRMT5 Inhibitor, Drives Antitumor Activity Preclinically and in Patients with MTAP-Deleted CancersBrian Belmontes, Katherine K Slemmons, Chun Su, et al.
Nature Cancer|July 3, 2020
Discovering the anti-cancer potential of non-oncology drugs by systematic viability profilingSteven M Corsello, Rohith T Nagari, Ryan D Spangler, et al.
Nature|July 6, 2017
Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathwayVasanthi S Viswanathan, Matthew J Ryan, Harshil D Dhruv, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 27, 2025
PI3Kα Inhibitor and Degrader Inavolisib Can Co-opt FGFR2 to Enhance Responses in Patients with PIK3CA-Mutated Solid Tumors and in Preclinical ModelsDejan Juric, Kyung Song, Radia M Johnson, et al.
Science Translational Medicine|September 3, 2025
An allele-agnostic mutant-KRAS inhibitor suppresses tumor maintenance signals and reprograms tumor immunity in pancreatic cancerKathleen M McAndrews, Francesca Paradiso, Clint A Stalnecker, et al.
Biorxiv : the Preprint Server for Biology|December 18, 2023
Tumor-selective effects of active RAS inhibition in pancreatic ductal adenocarcinomaUrszula N Wasko, Jingjing Jiang, Alvaro Curiel-Garcia, et al.
Nature Communications|June 5, 2019
Neuronal differentiation and cell-cycle programs mediate response to BET-bromodomain inhibition in MYC-driven medulloblastomaPratiti Bandopadhayay, Federica Piccioni, Ryan O'Rourke, et al.
Nature|May 6, 2026
Expanding the human proteome with microproteins and peptideinsEric W Deutsch, Leron W Kok, Jonathan M Mudge, et al.
Nature|April 8, 2024
Tumour-selective activity of RAS-GTP inhibition in pancreatic cancerUrszula N Wasko, Jingjing Jiang, Tanner C Dalton, et al.
Pageof 8